CO2019012888A2 - Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas - Google Patents
Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosasInfo
- Publication number
- CO2019012888A2 CO2019012888A2 CONC2019/0012888A CO2019012888A CO2019012888A2 CO 2019012888 A2 CO2019012888 A2 CO 2019012888A2 CO 2019012888 A CO2019012888 A CO 2019012888A CO 2019012888 A2 CO2019012888 A2 CO 2019012888A2
- Authority
- CO
- Colombia
- Prior art keywords
- antimitoskines
- stem cells
- cancer stem
- specific inhibitors
- mitochondrial biogenesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Los antibióticos que tienen propiedades anti-mitocondriales intrínsecas se pueden modificar químicamente para dirigir los antibióticos a las mitocondrias, y las "antimitoscinas" resultantes pueden tener propiedades anticancerosas mejoradas, entre otras propiedades ventajosas. También se describen métodos para identificar antimitoscinas, métodos para usar antimitoscinas para fijar como objetivo células madre cancerosas y composiciones farmacéuticas para tratar el cáncer que contienen una o más antimitoscinas como el ingrediente activo. También se dan a conocer compuestos específicos de antimitoscinas y grupos de antimitoscinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508702P | 2017-05-19 | 2017-05-19 | |
PCT/US2018/033466 WO2018213751A1 (en) | 2017-05-19 | 2018-05-18 | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019012888A2 true CO2019012888A2 (es) | 2020-05-15 |
Family
ID=64274780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0012888A CO2019012888A2 (es) | 2017-05-19 | 2019-11-18 | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas |
Country Status (20)
Country | Link |
---|---|
US (2) | US11160821B2 (es) |
EP (1) | EP3624840A4 (es) |
JP (1) | JP6938682B2 (es) |
KR (1) | KR20200010343A (es) |
CN (1) | CN111315400A (es) |
AU (1) | AU2018270129B2 (es) |
BR (1) | BR112019024264A2 (es) |
CA (1) | CA3063717C (es) |
CL (1) | CL2019003283A1 (es) |
CO (1) | CO2019012888A2 (es) |
CR (1) | CR20190524A (es) |
CU (1) | CU20190092A7 (es) |
DO (1) | DOP2019000294A (es) |
EC (1) | ECSP19082194A (es) |
IL (1) | IL270598B (es) |
MX (1) | MX2019013735A (es) |
PE (1) | PE20200605A1 (es) |
RU (1) | RU2019142102A (es) |
WO (1) | WO2018213751A1 (es) |
ZA (3) | ZA201907654B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
BR112019024264A2 (pt) | 2017-05-19 | 2020-06-02 | Lunella Biotech, Inc. | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer |
MX2019014806A (es) | 2017-06-26 | 2020-02-10 | Lunella Biotech Inc | Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas. |
CA3078791A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | Anti-mitochondrial inhibitors for oncogenic ras and myc |
EP3717015A4 (en) * | 2017-12-01 | 2021-07-28 | Lunella Biotech, Inc. | REPURPOSCINS: TARGET MITOCHONDRIAL BIOGENESIS INHIBITORS TO ERADICATE CARCINOUS STEM CELLS |
CR20210221A (es) | 2018-10-02 | 2021-06-24 | Lunella Biotech Inc | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
SG11202106532WA (en) | 2018-12-17 | 2021-07-29 | Lunella Biotech Inc | Triple combination therapies for anti-aging |
CN113573715A (zh) * | 2018-12-17 | 2021-10-29 | 卢内拉生物技术有限公司 | 用于靶向线粒体和杀死癌症干细胞的三联疗法 |
EP3976197A4 (en) * | 2019-05-24 | 2023-07-19 | Lunella Biotech, Inc. | THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER |
KR20220025849A (ko) * | 2019-06-26 | 2022-03-03 | 루넬라 바이오테크 인코포레이티드 | 미토콘드리아의 표적화 및 암 줄기 세포의 근절을 위한 카르보시아닌 화합물 |
WO2021081500A1 (en) | 2019-10-24 | 2021-04-29 | The Medical College Of Wisconsin, Inc. | Mitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug |
JP2023547108A (ja) * | 2020-10-22 | 2023-11-09 | ルネラ・バイオテック・インコーポレーテッド | γサブユニットを標的とするミトコンドリアATP阻害剤は転移を予防する |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2862921A (en) * | 1953-08-13 | 1958-12-02 | Upjohn Co | Erythromycin esters |
US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
US5795871A (en) | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
AU693013B2 (en) | 1995-05-03 | 1998-06-18 | Pfizer Inc. | Novel tetracycline derivatives |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
JP4590523B2 (ja) | 1997-11-25 | 2010-12-01 | アンティポディーン ファーマシューティカルズ インコーポレイテッド | ミトコンドリアを標的とする抗酸化剤 |
DE69919769T2 (de) | 1998-03-03 | 2005-01-27 | Pfizer Products Inc., Groton | 3,6-Ketal-Makrolidantibiotika |
AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
EP1461084A2 (en) * | 2001-12-11 | 2004-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Guanidinium transport reagents and conjugates |
US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
RU2223103C1 (ru) * | 2002-07-17 | 2004-02-10 | Открытое акционерное общество "Биосинтез" | Фармацевтическая композиция, обладающая антибактериальным действием |
WO2004069159A2 (en) | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US20070105937A1 (en) | 2003-12-22 | 2007-05-10 | Miguel Pappolla | Indole-3-propionamide and derivatives thereof |
JP2005200419A (ja) | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
US20050256081A1 (en) | 2004-02-26 | 2005-11-17 | Peyman Gholam A | Tetracycline derivatives for the treatment of ocular pathologies |
US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
JP5065910B2 (ja) | 2005-01-14 | 2012-11-07 | グラクソ グループ リミテッド | ビオチンおよび光親和性基を含む、マクロライド標的同定用のマクロライド化合物 |
CN1706391A (zh) * | 2005-05-09 | 2005-12-14 | 史同瑞 | 土霉素混悬乳剂 |
ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
CN1837229A (zh) * | 2005-08-05 | 2006-09-27 | 济南思创生物技术有限公司 | 克拉霉素衍生物及其制备方法和药物应用 |
DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
CN1837225A (zh) * | 2005-08-23 | 2006-09-27 | 济南思创生物技术有限公司 | 阿奇霉素衍生物及其制法和药物应用 |
MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
US20090311249A1 (en) | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
EP2079484A4 (en) | 2006-09-07 | 2010-03-17 | Stemline Therapeutics Inc | MONITORING OF CANCER STEM CELLS |
CN101631799A (zh) | 2006-10-30 | 2010-01-20 | 南方研究院 | 靶向nbs1-atm相互作用以使癌细胞对放射疗法及化学疗法敏感 |
PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
DE102007025423A1 (de) | 2007-05-30 | 2008-12-04 | Friedrich-Schiller-Universität Jena | Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung |
WO2008150845A1 (en) | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
US8647673B2 (en) | 2007-07-24 | 2014-02-11 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
KR20100074177A (ko) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | 미토콘드리아-표적화된 항-종양 물질 |
WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
US20100285001A1 (en) | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
SG175251A1 (en) | 2009-04-17 | 2011-11-28 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
GB0912584D0 (en) | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
AU2010292599A1 (en) | 2009-08-25 | 2012-03-15 | President And Fellows Of Harvard College | Use of metformin in cancer treatment and prevention |
EP2505188A1 (en) * | 2009-12-02 | 2012-10-03 | Bettina Heil | Suppository for rectal, vaginal or urethral administration |
CN109224064A (zh) | 2009-12-04 | 2019-01-18 | 昂科免疫有限公司 | 低氧诱导因子抑制剂的用途 |
EP2544692A4 (en) | 2010-03-10 | 2013-08-07 | Univ Health Network | USE OF TIGECYCLINE FOR THE TREATMENT OF CANCER |
CN101810570B (zh) * | 2010-04-16 | 2012-06-20 | 成都师创生物医药科技有限公司 | 蒽环类抗肿瘤抗生素脂肪酸复合物脂质纳米粒制剂及其制备方法 |
US20110268722A1 (en) * | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
ES2663368T3 (es) | 2011-02-10 | 2018-04-12 | Ruprecht-Karls-Universität Heidelberg | Péptidos modificados hidrófobos y uso de los mismos para su direccionamiento específico al hígado |
BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
WO2013007708A1 (en) | 2011-07-08 | 2013-01-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
US9801922B2 (en) | 2011-08-03 | 2017-10-31 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
CN102911226B (zh) * | 2011-08-03 | 2015-11-25 | 胡梨芳 | 硬脂酸红霉素类化合物物实体及其用途 |
WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
US9775855B2 (en) | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
CA2866080C (en) | 2012-03-01 | 2021-01-19 | University Of Cincinnati | Ros-activated compounds as selective anti-cancer therapeutics |
WO2014036037A1 (en) | 2012-08-28 | 2014-03-06 | Annam Biosciences, Llc | N-boc-dendrimers and their conjugates |
WO2014036654A1 (en) | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
CN105142631A (zh) | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
PL2989110T3 (pl) | 2013-04-24 | 2019-03-29 | Smart Brain s.r.o. | Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2 |
US10004809B2 (en) | 2013-07-01 | 2018-06-26 | University Of Georgia Research Foundation Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
WO2015050844A1 (en) | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
CN103536530A (zh) * | 2013-10-30 | 2014-01-29 | 王玉万 | 盐酸多西环素长效注射剂及制备方法 |
CA2843943A1 (en) | 2014-02-20 | 2014-05-28 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
WO2015191668A1 (en) | 2014-06-10 | 2015-12-17 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
WO2016059247A1 (en) | 2014-10-17 | 2016-04-21 | Targeted Therapies Research And Consulting Centre Sprl (Ttrcc) | Multi-ingredient pharmaceutical composition for use in cancer therapy |
CN104352566A (zh) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | 一种水包油型复方金霉素纳米乳 |
JP6439931B2 (ja) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | 吸着搬送装置および吸着搬送方法 |
EP3359255A4 (en) | 2015-10-06 | 2019-06-12 | Redhill Biopharma Ltd. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
CN105884633B (zh) * | 2016-05-07 | 2017-12-26 | 浙江大学 | 一种四环素硬脂酸嫁接物及其制备和应用 |
JP2019528689A (ja) | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫調節化合物 |
CN106511317A (zh) * | 2016-12-13 | 2017-03-22 | 浙江中同科技有限公司 | 一种掩味克拉霉素颗粒的制备方法 |
WO2018136617A2 (en) | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
US20190365830A1 (en) | 2017-01-18 | 2019-12-05 | Evelo Biosciences, Inc. | Methods of treating cancer |
EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
BR112019024264A2 (pt) | 2017-05-19 | 2020-06-02 | Lunella Biotech, Inc. | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer |
WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
MX2020005311A (es) | 2017-11-24 | 2020-08-17 | Lunella Biotech Inc | Compuestos de derivados de trifenilfosfonio para erradicar celulas madre cancerosas. |
US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
-
2018
- 2018-05-18 BR BR112019024264-3A patent/BR112019024264A2/pt unknown
- 2018-05-18 CN CN201880046651.0A patent/CN111315400A/zh active Pending
- 2018-05-18 CR CR20190524A patent/CR20190524A/es unknown
- 2018-05-18 WO PCT/US2018/033466 patent/WO2018213751A1/en active Search and Examination
- 2018-05-18 CU CU2019000092A patent/CU20190092A7/es unknown
- 2018-05-18 MX MX2019013735A patent/MX2019013735A/es unknown
- 2018-05-18 US US16/614,623 patent/US11160821B2/en active Active
- 2018-05-18 JP JP2019563871A patent/JP6938682B2/ja active Active
- 2018-05-18 EP EP18803298.1A patent/EP3624840A4/en active Pending
- 2018-05-18 RU RU2019142102A patent/RU2019142102A/ru not_active Application Discontinuation
- 2018-05-18 CA CA3063717A patent/CA3063717C/en active Active
- 2018-05-18 AU AU2018270129A patent/AU2018270129B2/en active Active
- 2018-05-18 KR KR1020197037193A patent/KR20200010343A/ko not_active Application Discontinuation
- 2018-05-18 PE PE2019002430A patent/PE20200605A1/es unknown
-
2019
- 2019-11-12 IL IL270598A patent/IL270598B/en unknown
- 2019-11-15 CL CL2019003283A patent/CL2019003283A1/es unknown
- 2019-11-18 CO CONC2019/0012888A patent/CO2019012888A2/es unknown
- 2019-11-19 DO DO2019000294A patent/DOP2019000294A/es unknown
- 2019-11-19 ZA ZA2019/07654A patent/ZA201907654B/en unknown
- 2019-11-19 EC ECSENADI201982194A patent/ECSP19082194A/es unknown
-
2021
- 2021-04-16 ZA ZA2021/02509A patent/ZA202102509B/en unknown
- 2021-10-01 US US17/491,672 patent/US11865130B2/en active Active
-
2022
- 2022-03-07 ZA ZA2022/02712A patent/ZA202202712B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3624840A4 (en) | 2021-03-10 |
MX2019013735A (es) | 2020-01-15 |
CA3063717C (en) | 2021-08-24 |
JP6938682B2 (ja) | 2021-09-22 |
CL2019003283A1 (es) | 2020-05-04 |
AU2018270129A1 (en) | 2020-01-16 |
RU2019142102A (ru) | 2021-06-21 |
US20220072020A1 (en) | 2022-03-10 |
ZA202102509B (en) | 2023-03-29 |
CR20190524A (es) | 2020-01-10 |
US11160821B2 (en) | 2021-11-02 |
RU2019142102A3 (es) | 2021-06-21 |
ECSP19082194A (es) | 2019-11-30 |
ZA201907654B (en) | 2022-07-27 |
AU2018270129B2 (en) | 2021-01-07 |
NZ760422A (en) | 2023-11-24 |
CA3063717A1 (en) | 2018-11-22 |
CN111315400A (zh) | 2020-06-19 |
PE20200605A1 (es) | 2020-03-10 |
CU20190092A7 (es) | 2020-10-20 |
IL270598B (en) | 2022-04-01 |
EP3624840A1 (en) | 2020-03-25 |
DOP2019000294A (es) | 2020-02-16 |
BR112019024264A2 (pt) | 2020-06-02 |
ZA202202712B (en) | 2023-11-29 |
US11865130B2 (en) | 2024-01-09 |
KR20200010343A (ko) | 2020-01-30 |
US20200179424A1 (en) | 2020-06-11 |
JP2020527127A (ja) | 2020-09-03 |
WO2018213751A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19082194A (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
CR20150523A (es) | Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas | |
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CL2018001996A1 (es) | Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16) | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
NI202000031A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
ECSP15003613A (es) | Formulación transdérmica que contiene inhibidores de cox | |
BR112017004304A2 (pt) | composições de pteroestilbeno tópicas para uso em tratamento de perda de função de barreira na pele induzidas por uv | |
CO2020006648A2 (es) | Derivados de imidazopiridina y su uso como medicamento | |
BR112015014367A2 (pt) | formulações inibidoras de lfa-1 | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
CO2021004612A2 (es) | Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento | |
AR110648A1 (es) | Composiciones veterinarias y los usos de las mismas para prevenir y/o tratar infecciones parasitarias en mamíferos no humanos y kit | |
CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. |